Efficacy of Topotecan as a Second-Line Treatment of Small-Cell Lung Cancer in Patients with Refractory and Sensitive Disease: Retrospective Study

PURPOSE: Chemotherapy is the treatment of choice for small-cell lung cancer (SCLC). Despite the high response rates with first-line therapy, most patients eventually experience disease progression, and finally become candidates for second-line therapy. Topotecan is the only single agent currently approved in the United States for the treatment of a recurrent disease. The aim of this study was to evaluate its efficacy in patients with of previously treated, but relapsed and refractory, SCLC. MATERIALS AND METHODS: Twenty-five patients, who had taken topotecan as a second-line therapy, between March 1999 and October 2002, were reviewed. The patients were divided into two groups: (1) One group were the patients that had failed the first-line treatment within 3 months from end of the chemotherapy (refractory group, RG); and (2) the other group were those that responded to the first-line treatment, but who progressed 3 months after the end of the chemotherapy (sensitive group, SG). Topotecan was administered, intravenously, at a dose of 1.5 mg/m2, within 30 minutes, for five consecutive days every 3 weeks. RESULTS: There was only one partial response in the SG (3.8%), but there were 9 stable diseases, 4 in the SG and 5 in the RG; 15.4 and 19.2%, respectively. The median survivals were 6.9 and 5.2 months in SG and RG, respectively (p=0.162). There were ninety-nine chemotherapy cycles. The toxicities were mainly hematological. There were 26 incidences of Grades III and IV neutropenia, and the non hematological toxicities were mild. CONCLUSION: It was concluded that topotecan is not so effective in the treatment of patients with relapsed and refractory SCLC, despite its predictable and manageable toxicity. The incorporation of topotecan in combination chemotherapy regimens for treatment of SCLC is now warranted.

Surgical Outcome of Idiopathic Normal Pressure Hydrocephalus according to the Shunt Devices

OBJECTIVE: To determine the effect of shunt devices on the surgical outcome in the idiopathic normal pressure hydrocephalus(NPH), the authors present a retrospective analysis of 39 elderly patients who underwent shunt operations between November 1994 and May 2000, retrospectively. METHODS: The patients enrolled in this study did not have the history of intracranial hemorrhage, head injury, infection, cerebral infarction and brain tumor. The mean age was 69.9(range:52-89) years. Thirteen patients who received operations with simple pressure-control shunt valves(Group I), 22 patients with siphon-control shunt valves(Group II), and four patients with flow-regulating shunt valves (Group III). Final outcome with the clinical improvement and shunt associated complications were evaluated at the last follow-up and the mean follow-up period was 14.7 months. RESULTS: Signs or symptoms of shunt dysfunction were found in eight of 39 patients(20.5%) in the subsequent course. In group I, five out of 13 patients had suffered from symptomatic subdural hematomas and one from overdrainage symptoms(46.2%);in group II, two out of 22 from underdrainage(9%);in group III, one out of four from symptomatic subdural hematomas(25%). Five patients required operative shunt revisions and five underwent burr-hole trephinations for subdural hematomas. Clinical improvements were observed in 10(79.6%), 19(86.4%), and 3(75%) patients in group I, II, and III respectively. Surgical outcomes were better for patients with siphon-control shunt valves than there with the other shunt valves in terms of shunt associated complications and functional improvements(p=0.05). CONCLUSION: The shunt operation with siphon-control shunt valves might be good for the elderly patients with idiopathic NPH.

Antitumor and Antimetastatic Effects of Toxoplasma Gondii in Mice with Lewis Lung Carcinoma / 결핵

BACKGROUND: Immunotherapy is another treatment modality for various cancers. There is little information on the antitumor effects of immunotherapy on implanted lung cancer mouse models. Toxoplasma gondii is able to potently induce a nonspecific stimulation of the host immune system. Therefore, this study evaluated the antitumor and antimetastatic effect of nonspecific immune stimulation by T. gondii in a Lewis lung cancer mouse model. METHODS: Femals C57BL/6 mice were injected with either Lewis lung cancer cells (1 X 10(6) per mouse) or 5 cysts from the T. gondii Me49 strain with various schedules. The number of survival days, the tumor size of the implanted muscle and the histopathological findings of each group were noted. In addition to these mice, the Toxoplasma antigen(50 micro gram per mouse) or a lymphokine (0.5ml per mouse) was added to boost the immunotherapy. RESULTS: No mouse in the Toxoplasma-infected group had died, whereas the mice receiving only the cancer cells (cancer control) survived for 29.1+/-4.4days. Cancer cells were revealed from 1 week after cancer cell inoculation in the muscle and from 3 weeks in the lung of the cancer control, whereas cancer cells were found in both the preinfection control and coinfection control groups from 2 weeks and 4 weeks in the lung, respectively. The in the number of survival days were 32.4+/-3.3 in the mice receiving T. gondii 2 weeks prior to the cancer cells inoculation (preinfection control), 30.9+/-5.1 in mice received both simultaneously (coinfection control), and 34.9+/-2.9 in mice received T.gondii 2 weeks after cancer cells implantation (postinfection control). These 3 infection groups had significantly longer survival days and suppressed tumor growth than those of the cancer control. In addition to these mice, and injection with the Toxoplasma antigen alone or in combination with lymphokine resulted in a significant increase in the number of survival days. CONCLUSIONS: These findings suggest that an injection with T.gondii can induce the antitumor and antimetastatic effects in Lewis lung cancer mouse models. Moreover, these effects were increased with an injection of the Toxoplasma antigen alone or in combination with lymphokine. However, this therapy can not prevent the development of cancer.